Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis

Allergic bronchopulmonary aspergillosis (ABPA) is a severe lung disease complication caused by an Aspergillus fumigatus-induced hypersensitivity that affects 2 –15% of patients with cystic fibrosis (CF). The mainstay treatment consists of a combination of corticosteroids and antifungals. However, repeated or long-term corticosteroid therapies can lead to serious side effects. The monoclonal anti-IgE antibody, omalizumab, has demonstrated its efficacy in allergic asthma. As ABPA results from a hypersensitivity to a specific allergen, omalizumab might benefit CF patients with ABPA.

Source: Respiratory Medicine - November 9, 2017 Category: Respiratory Medicine Authors: Caroline Perisson, Leila Destruys, Dominique Grenet, Laurence Bassinet, Jocelyne Derelle, Isabelle Sermet-Gaudelus, Caroline Thumerelle, Anne Prevotat, Vincent Rosner, Annick Clement, Harriet Corvol Tags: Short communication Source Type: research